Pizuglanstat

• Description :

  Pizuglanstat (Compound 3; TAS-205 free base) is an orally active prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. Pizuglanstat inhibits the synthesis of PGD2. Pizuglanstat improves experimental allergic rhinitis. Pizuglanstat can be used in the study of muscle regenerative diseases such as muscular dystrophy[1][2][3].

• Product Name Alternative :

  TAS-205 (free base)

• UNSPSC :

  12352005

• Target :

  Prostaglandin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pizuglanstat.html

• Purity :

  99.70

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic)

• Smiles :

  O=C(N1CCOCC1)C2CCN(C3=CC=C(NC(N4CCN(C(C5=CC=CN5C)=O)CC4)=O)C=C3)CC2

• Molecular Formula :

  C27H36N6O4

• Molecular Weight :

  508.61

• References & Citations :

  [1]Yoshihiro Urade, et al. Piperazine compound capable of inhibiting prostaglandin D synthase. United States. US8865714B2. 2010-03-08.|[2]Aoyagi H, et al. Potential synergistic effects of novel hematopoietic prostaglandin D synthase inhibitor TAS-205 and different types of anti-allergic medicine on nasal obstruction in a Guinea pig model of experimental allergic rhinitis. Eur J Pharmacol. 2020 May 15;875:173030.|[3]Komaki H, et al. Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2020 Feb;7 (2) :181-190.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  DP

• CAS Number :

  [1244967-98-3]